Editor's Note: This story was last updated on Feb. 1, 2021.
A scary new strain of coronavirus, innocuously named B.1.1.7, has recently exploded across southeast England, prompting the government to tighten lockdowns on the region. Though we don't know all the details, experts are increasingly confident it is more easily transmitted than other strains. Here's everything we know so far about this novel strain.
What is it?
The B.1.1.7 strain of SARS-CoV-2 is a version of the virus with 23 mutations, eight of which are in the spike protein the virus uses to bind to and enter human cells, Science Magazine reported.
Where did it come from?
It was first detected Sept. 21 in Kent County in England, then took off and spread in November, according to the World Health Organization.
Since then, it has become the most common variant in England, representing more than 50% of new cases diagnosed between October and Dec. 13 in the U.K., according to the WHO.
However, some scientists now believe that the virus may have mutated in a person who was immunocompromised, according to Science Magazine. That's because, unlike the flu, the novel coronavirus can correct mistakes when it replicates, and so tends to have a fairly stable genome, Live Science previously reported. However, studies have shown that people who have weakened immune systems — because they are taking immunosuppressant drugs or are being treated with chemotherapy, for instance — may harbor infectious virus for months. That, in turn, would give the virus many chances to acquire mutations that help it replicate or evade the immune system.
What do these mutations do?
We don't know for sure. Viruses mutate all the time, and most of these changes don't affect how deadly or infectious the virus is. In this case, some of these mutations may have arisen purely by chance and may not affect the function of the virus.
But three mutations in particular have worried experts.
One, a two amino-acid deletion known as 69-70Del, was first detected separately in a patient being treated with immunosuppressants who developed COVID-19. The patient received remdesevir, convalescent plasma and neutralizing antibodies, but died months later. Though the virus did not initially have this deletion, it acquired it over months, researchers reported in a preprint article published Dec. 19 to the medRiv database. (It has not been peer-reviewed.) The authors suspect it evolved to evade the immune system. Another wrinkle associated with this deletion is that it can make one of the targets of SARS-CoV-2 PCR tests — known as the S gene — falsely test negative. Some tests only look for positives in this S gene and would therefore miss the new variant. Most PCR assays, however, look for three separate regions of the spike protein, so those assays won't be affected, the WHO said.
Another mutation, known as N501Y, alters the key amino acids that make up the so-called receptor-binding domain of SARS-CoV-2, where amino acid asparagine (N) has been replaced with tyrosine (Y) in the part of the virus that latches onto the ACE2 receptor on human cells, according to the Centers for Disease Control and Prevention. A September study in the journal Cell found this variant binds more tightly to the ACE2 receptor than other versions of the coronavirus — at least in a lab dish.
Dozens of samples of SARS-CoV-2 from South Africa and Australia have tested positive for this mutation, but lab tests suggest the South African and U.K. variants separately evolved the same mutation. That suggests it may provide an evolutionary advantage to the virus.
The third suspicious mutation is P681H, which is also in the receptor-binding domain of the virus. According to preliminary information posted by the COVID-19 Genomics Consortium UK, this mutation sits next to the "furin cleavage site," which is where the spike protein must be cleaved in order for the virus to enter cells, according to Science Magazine.
Does it spread more easily?
Yes. Experts now think the new variant is between 50% and 74% more transmissible than other dominant strains, according to a study by the Center for Mathematical Modeling and Infectious Diseases (CMMID) that has not yet been peer-reviewed. The WHO estimates this would tack on 0.4 to the basic reproductive number R, which dictates how many people each infected person would spread the virus to.
Based on models of that growth, the new variant could be responsible for 90% of all new COVID-19 cases in London and East and South England by mid-January, that study found.
Another study from the U.K., published Dec. 27 to medrXiv and also not peer reviewed, found higher viral loads in PCR tests that are negative for the S gene. Testing negative for the S gene means the virus has the 69-70Del mutation and so such S-gene dropouts are thus a proxy for, but not a certain indication of, the samples coming from the B.1.1.7 variant. And a higher viral load makes it easier for the virus to spread.
Is it more deadly?
Maybe. Early evidence from the U.K. hints that the variant may be 30% more deadly, officials said at a news briefing on Jan. 22. However, officials stressed that the evidence for this was still very uncertain, Live Science previously reported.
Has the variant spread to the U.S.?
Yes. On Dec. 29, Colorado Gov. Jared Polis announced that the variant had been detected in a man in his 20s in the state. Whether the virus has spread further is still unknown, but seems increasingly likely.
That's because America has not done nearly as much genetic sequencing on viral samples as the U.K. has. For instance, as of December, the U.S. had sequenced 51,000 viral samples out of 17 million identified cases of SARS-CoV-2, according to the CDC. The U.K. has sequenced more than twice as many viral samples as the U.S., despite having slightly more than a tenth of the diagnosed cases.
Dr. Stanley Perlman, an immunologist and pediatric infectious diseases specialist at the University of Iowa, previously told the Center for Infectious Disease Research and Policy (CIDRAP) that he suspected the variant is already in the U.S. "I'd be surprised if it weren't," he said.
One indication that the variant is spreading could be an increasing number of positive PCR tests that test negative for the S gene. On Dec. 23, scientists with Helix, a company that has administered at least 2 million COVID-19 PCR tests, wrote in a blog post that the incidence of such S-gene dropouts in their samples started increasing in October. As of mid-December, about 0.5% of the company's positive tests are so-called S-gene dropouts, coming from at least 14 states, including California, Florida, New York and Texas. (Colorado was not one of those states.) However, this doesn't necessarily mean B.1.1.7 is spreading in multiple U.S. states. That's because S-gene dropouts only indicate that the virus being sampled likely has the 69-70Del mutation; it doesn't reveal whether the sample also contains the other two significant mutations associated with B.1.1.7.
And on the flip side, because Helix only administers some of the country's PCR tests, they may be missing some states where S-gene dropouts are on the rise.
Can kids catch it more easily?
Several lines of evidence in the past have suggested kids might be less susceptible to the novel coronavirus. If this new variant sticks more easily to cells, there's the chance it could spread more readily amongst children than it did before. However, further studies will be needed to see whether that's the case.
There has been an uptick in cases in children in England at the same time that this virus has increased its prevalence. That uptick was not seen when kids first returned to schools in early fall. But schools were open while many other things were closed at this time, so it's possible schools represented one of relatively few chances the virus had to spread. We can't yet say that kids will catch and spread this variant more readily.
Will vaccines work against the new virus?
Most experts think the newly developed vaccines will still work against the novel U.K. variant. When vaccines stimulate the immune system, the body builds an arsenal of cells to bind to many different parts of the virus. Mutations in a handful of spots will likely not be enough to make the vaccine less effective, according to the CDC.
Given that 99% of the proteins on the new variant are identical to the strain the Pfizer-BioNtech mRNA vaccine targets (the Moderna vaccine is very similar), it is highly likely that the vaccine will work, BioNTech CEO Uğur Şahin said at a news briefing.
It's possible that over time a variant could emerge that will evade some of our vaccines, similar to how the flu vaccine needs to be updated every year. However, the new mRNA vaccines could be updated to reflect new mutations in about six weeks, Şahin told the Financial Times.
What can we do to stop this?
The new variant still spreads the same way as the ordinary form of the coronavirus. That means the same things everyone has been doing to prevent the spread of the virus since March will also work for the new U.K. variant: washing hands, physical distancing, masks and good ventilation. Adhering strictly to those rules and avoiding unnecessary outings will help prevent its spread.
Originally published on Live Science.
Live Science newsletter
Stay up to date on the latest science news by signing up for our Essentials newsletter.
Tia is the managing editor and was previously a senior writer for Live Science. Her work has appeared in Scientific American, Wired.com and other outlets. She holds a master's degree in bioengineering from the University of Washington, a graduate certificate in science writing from UC Santa Cruz and a bachelor's degree in mechanical engineering from the University of Texas at Austin. Tia was part of a team at the Milwaukee Journal Sentinel that published the Empty Cradles series on preterm births, which won multiple awards, including the 2012 Casey Medal for Meritorious Journalism.
By Sascha Pare
By Ben Turner
By Sascha Pare
By Harry Baker
By Ben Turner